Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04862676 · ClinicalTrials.gov registry record · Early Phase 1
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
A Early Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
NCT04862676 is a Early Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 29 participants.
The verdict
NCT04862676, a Early Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.
Interventions
- DRUG Hyperbaric oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04862676
The ClinicalTrials.gov registry entry for NCT04862676 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperbaric oxygen is the first listed.
NCT04862676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04862676 about?
NCT04862676 is a clinical study titled "Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT". Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.
What is the current status of trial NCT04862676?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2022-04-22. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04862676?
The interventions under investigation include: Hyperbaric oxygen (DRUG).
Who is sponsoring clinical trial NCT04862676?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.